Axitinib

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 17, 2022
Mutation, PID, State Administrative Expenses, Conference, Risk, Pids, Immunoglobulin M, G&A, EDT, Lymphocyte, U.S. Securities and Exchange Commission, Severe congenital neutropenia, WHIM syndrome, SEC, R rating, Private Securities Litigation Reform Act, AACR, COVID-19, Medication, Wart, Forward-looking statement, Completeness, Clinical trial, Neutrophil, Research, Cancer, Immune system, Research and development, Genetic testing, Society, Oral, CIS, Conference call, Monocyte, Therapy, ASH, Security (finance), Prevalence, Clear cell renal cell carcinoma, Achievement, Disease, GLOBE, ID, Immunodeficiency, SCN, Safety, Adult, Axitinib, R, Biology, Pharmaceutical industry, Vaccine, Lithium, Infection, Hypogammaglobulinemia, CXCR4, Patient

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update.

Key Points: 
  • Top-line data from the 4WHIM trial are expected in the fourth quarter of 2022.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $83.1 million in cash, cash equivalents, and restricted cash as of December 31, 2021.
  • The company expects that its cash and cash equivalents will fund company operations into the fourth quarter of 2022.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.

Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 10, 2022
Bausch & Lomb, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Investor, Suprachoroidal drug delivery, Private Securities Litigation Reform Act, Therapeutic index, Conference call, Pharming, Retina, ET, Diabetic retinopathy, Safety, AMD, Uveitis, Company, Axitinib, GLOBE, Patient, Macular edema, SEC, Review, NASDAQ, Clinical trial, SCS, Choroid, Periodic Report of the United States of America to the United Nations Committee Against Torture, American Academy of Ophthalmology, Annual report, Conference, Acral lentiginous melanoma, U.S. Securities and Exchange Commission, Leadership, Sale, Eye, Income, Cohort, Webcast, Research, Technology, COVID-19, Toxic leukoencephalopathy, Angiogenesis, Food, Pharmaceutical industry, Video game, Animal, Clearside, Ophthalmology

ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., March 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
  • Clearsides license and other revenue for the fourth quarter of 2021 was $25.7 million, compared to $11,000 for the fourth quarter of 2020.
  • Research and development expenses for the fourth quarter of 2021 were $3.8 million, compared to $4.5 million for the fourth quarter of 2020.
  • General and administrative expenses for the fourth quarter of 2021 were $3.1 million, compared to $2.6 million for the fourth quarter of 2020.

Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors

Retrieved on: 
星期四, 三月 3, 2022
Private Securities Litigation Reform Act, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Ophthalmology, Patient, Research, Choroid, Population, Eye, University of California, Irvine Medical Center, Biotechnology, Food, U.S. Securities and Exchange Commission, Annual report, Foundation Fighting Blindness, University, Genta (company), Board of directors, Periodic Report of the United States of America to the United Nations Committee Against Torture, Sclera, Lung, Chemistry, SEC, Company, Board, COVID-19, HIV, Axitinib, CEO, Retina, University of California, San Diego Performance-Based Skills Assessment, SCS, Visual impairment, Technology, Diabetes, Drug discovery, Nasdaq, GLOBE, Foundation, Pharmaceutical industry, Clearside

Clearsides innovative suprachoroidal delivery approach offers an attractive treatment option to address these needs.

Key Points: 
  • Clearsides innovative suprachoroidal delivery approach offers an attractive treatment option to address these needs.
  • Dr. Yerxa serves on the Board of Directors of the North Carolina Biotechnology Center and several private ophthalmic companies, including Nacuity Pharmaceuticals and Sparing Vision.
  • Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Ocular Therapeutix™ to Present at the Cowen 42nd Annual Healthcare Conference

Retrieved on: 
星期五, 三月 4, 2022
Biotechnology, Pharmaceutical, Optical, Health, Duane syndrome, Ocular hypertension, Patient, Intraocular pressure, Eye, FDA, Retina, Conference, Inflammation, Pain, NASDAQ, Axitinib, AMD, Allergic conjunctivitis, Pharmaceutical industry

Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen representative.

Key Points: 
  • Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Cowen representative.
  • Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

Retrieved on: 
星期一, 二月 28, 2022
Health, Research, Pharmaceutical, Science, Optical, Biotechnology, Eye, Sealant, Depreciation, Travoprost, Omicron, ITT, Dexamethasone, Compliance, Investor, Population, Allergic conjunctivitis, Webcast, International, IOP, Glaucoma, Pain, Inflammation, Intraocular pressure, Security (finance), NASDAQ, Slit lamp, ID, Research, Retina, COVID-19, Duane syndrome, Company, Angiogenesis, Quarter, Clinical trial, Safety, G&A, U.S. Securities and Exchange Commission, Review, AMD, Axitinib, KAMS, Private Securities Litigation Reform Act, FDA, Patient, Marketing, Ocular hypertension, Royal, Software, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, Ocular Therapeutix, Inc., DEXTENZA, OCULAR THERAPEUTIX, INC., DEXTENZA

In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.

Key Points: 
  • In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.
  • In October 2021, the Company received supplemental FDA approval expanding DEXTENZAs label to include the treatment of ocular itching associated with allergic conjunctivitis.
  • General and administrative expenses were $7.5 million for the fourth quarter versus $6.6 million in the comparable quarter of 2020.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

Retrieved on: 
星期二, 二月 22, 2022
Biotechnology, Pharmaceutical, Optical, Health, Eye, Investor, Allergic conjunctivitis, Webcast, International, Pain, Inflammation, Intraocular pressure, ID, Retina, AMD, Axitinib, FDA, Duane syndrome, Patient, Ocular hypertension, Software, Pharmaceutical industry

Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close.

Key Points: 
  • Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close.
  • Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Companys financial results and provide a general business update.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

Retrieved on: 
星期五, 二月 11, 2022
Biotechnology, FDA, Health, Pharmaceutical, Optical, Other Science, Research, Hospitals, Surgery, Science, Clinical Trials, NASDAQ, Private Securities Litigation Reform Act, Patient, Allergic conjunctivitis, Ocular hypertension, Duane syndrome, Company, Travoprost, U.S. Securities and Exchange Commission, Pressure, Security (finance), Intraocular pressure, Glaucoma, Clinical trial, Intention, Pain, Compliance, MD, AMD, FDA, Axitinib, Eye, Angiogenesis, Inflammation, Retina, Associate, COVID-19, MBA, Pharmaceutical industry, Ophthalmology

The Company will also present data from the Phase 1 US-based clinical trial of OTX-TIC, an intracameral implant of travoprost for the treatment of glaucoma and ocular hypertension at the Glaucoma 360 Meeting on February 11th.

Key Points: 
  • The Company will also present data from the Phase 1 US-based clinical trial of OTX-TIC, an intracameral implant of travoprost for the treatment of glaucoma and ocular hypertension at the Glaucoma 360 Meeting on February 11th.
  • The presentations being made at these two medical meetings can be accessed February 12th on the Events and Presentations section of the Ocular Therapeutix website.
  • OTX-TIC (travoprost intracameral implant) recently began a Phase 2 clinical trial for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022

Retrieved on: 
星期三, 二月 2, 2022
Growth, Eye, Safety, Patient, Food, Retina, Choroid, VEGF, Sclera, TKI, SCS, OASIS, Squamous cell carcinoma, Axitinib, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AMD, Pharmaceutical industry, Clearside

Clearsides patented, proprietary suprachoroidal space (SCS) injection platform offers unprecedented access to the back of the eye where sight-threatening disease often occurs.

Key Points: 
  • Clearsides patented, proprietary suprachoroidal space (SCS) injection platform offers unprecedented access to the back of the eye where sight-threatening disease often occurs.
  • The companys unique platform is inherently flexible and intended to work with established and new formulations of medications.
  • Clearsides proprietary SCS Microinjector can be used to inject a wide variety of drug candidates into the SCS.
  • Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in preclinical studies in multiple species.

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

Retrieved on: 
星期二, 一月 18, 2022
Health, Surgery, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, IQVIA, Patient, Eye, Inflammation, Private Securities Litigation Reform Act, Clinical trial, Dexamethasone, COVID-19, AMD, Safety, Growth, NASDAQ, ASEAN, ASEAN countries in sporting events, Axitinib, U.S. Securities and Exchange Commission, Duane syndrome, Pain, Therapy, Allergic conjunctivitis, Company, Retina, FDA, Intraocular pressure, Compliance, Security (finance), Ocular hypertension, Pharmaceutical industry, Ocular Therapeutix, Inc., AffaMed Therapeutics, DEXTENZA®, OCULAR THERAPEUTIX, INC., AFFAMED THERAPEUTICS, DEXTENZA®

In 2020, Ocular entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of DEXTENZA in Greater China, South Korea, and the ASEAN markets.

Key Points: 
  • In 2020, Ocular entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of DEXTENZA in Greater China, South Korea, and the ASEAN markets.
  • This prospective, single-arm, real-world trial is designed to assess the safety and efficacy of DEXTENZA for the treatment of ocular inflammation and pain following cataract surgery in approximately 120 patients at the Boao Super Hospital.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
  • DEXTENZA is FDA approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Retrieved on: 
星期二, 一月 4, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Other Health, Axitinib, Event-driven architecture, Investor, Intraocular pressure, Ocular hypertension, Patient, Allergic conjunctivitis, Conference, AMD, FDA, Eye, Inflammation, Pain, Duane syndrome, Retina, Pharmaceutical industry

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

Key Points: 
  • Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.
  • Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.
  • Ocular Therapeutix's first product, ReSure Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.